source
- Revolution Medicines sees strong demand for pancreatic cancer drug daraxonrasib under compassionate useRevolution Medicines reports that more than 2,000 patients have received its pancreatic cancer candidate daraxonrasib through a compassionate use program. The company says the drug has been distri…
- Replimune secures FDA accelerated approval for melanoma therapy TudriqevReplimune announced that the FDA has granted accelerated approval to its melanoma therapy RP1, marketed as Tudriqev, after two earlier rejections and a third expedited review. The decision reflects…